Endometriosis
Conditions
Keywords
AGES (Advanced Glycation End Products)
Brief summary
Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.
Detailed description
Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.
Interventions
OTHERAdvanced Glycation End Products (AGEs)
Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
Sponsors
Kanuni Sultan Suleyman Training and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* diagnosed with endometriosis (Surgery or ultrasound) * Women without endometriosis
Exclusion criteria
* Women without endometriosis women who are only suspected endometriosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis | 8 months | Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage | 8 months | By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined. |
Countries
Turkey (Türkiye)
Outcome results
None listed